Parabilis now the largest VC-backed biotech IPO
Parabilis Medicines’ $745M IPO redefines biotech funding—now the largest VC-backed debut in history.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Parabilis Medicines has completed its initial public offering (IPO) on NASDAQ, raising $745 million after upsizing its deal. The company’s shares surged 67% on debut, propelling its market capitalization to $3.7 billion—the largest VC-backed biotech IPO to date. Coverage highlights its focus on targeting previously 'undruggable' diseases, positioning it as a leader in high-risk, high-reward drug development.
Financial and biotech media outlets, including Bloomberg, WSJ, and BioSpace, emphasize the IPO’s record-breaking valuation and the broader market signal it sends. The surge follows a trend of high-profile biotech IPOs, though analysts note the optimism is concentrated in companies with reduced development risk. Watch for investor reactions to Parabilis’ pipeline progress and whether its success spurs more VC-backed biotechs to pursue IPOs.
Coverage also suggests scrutiny of whether the market can sustain valuations for early-stage biotech firms beyond the 'derisked' subset.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 154d ago.
Quick answers
What is Parabilis Medicines’ market cap after its IPO?
Parabilis Medicines’ market cap reached $3.7 billion following its first day of trading on NASDAQ.
How much did Parabilis raise in its IPO?
Parabilis raised $745 million after upsizing its initial public offering.
What distinguishes Parabilis from other biotech IPOs?
Parabilis is noted for targeting 'undruggable' diseases and has become the largest VC-backed biotech IPO to date, signaling confidence in its high-risk, high-reward approach.
Coverage (10)
- 'Going for our own moonshot': Parabilis CEO on biotech's record IPO Endpoints News · 156d ago
- Parabilis Medicines Rings the Closing Bell Nasdaq · 156d ago
- Drugmaker Parabilis Soars 67% After $745 Million IPO, Placement Bloomberg.com · 156d ago
- Parabilis soars to $3.7B market cap after first day on NASDAQ FirstWord Pharma · 156d ago
- Parabilis Medicines Shares Rocket Following Record Biotech IPO WSJ · 156d ago
- Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO MedCity News · 156d ago
- Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs BioSpace · 156d ago
- Parabilis Medicines Announces Pricing of Upsized Initial Public Offering Stock Titan · 156d ago
- Parabilis sets a record with a $670M biotech IPO BioPharma Dive · 156d ago
- Parabilis now the largest VC-backed biotech IPO Yahoo Finance · 156d ago
Topics
Related trends
What the Nvidia scandal means for the company's earnings next week
Upcoming Nvidia earnings reports spark market attention amid leadership transitions and corporate scrutiny.
Stocks Slide on Nvidia Troubles, Oil Edges Lower: Markets Wrap
Global markets react as Nvidia shares tumble following the exit and resignation of boss Jensen Huang.
The Only Thing Driving Truth Social's Revenue Will Make You Close Your Eyes and Wish for Better Days
Trump Media swings to a quarterly profit as revenue triples, driven largely by high-speed access to Truth Social posts via the Truth API.
Why Sandisk and Lumentum Are Leading the AI Comeback
Sandisk surged 16% as a storage rally returned ahead of an 8-for-1 split, while Barron's framed Sandisk and Lumentum as leaders of an AI comeback.
Costco’s Special Dividend Is Just One Reason It’s a Good Place to Shelter From AI Chaos
Costco's first special dividend in nearly three years, paired with a $4 billion buyback, is drawing attention as investors consider where to sit amid AI-driven market disruption.
We’ve never seen anything like the Anthropic IPO
Anthropic filed for an IPO seeking a $1.3 trillion valuation, pricing 825 million shares at $70-$78 to raise over $61 billion.